Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abou-Saleh MT, Coppen A: Who responds to prophylactic lithium? J Affect Disord 1986,10(2):115–125. 10.1016/0165-0327(86)90034-0
Amsterdam JD, Shults J: Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010,167(7):792–800. 10.1176/appi.ajp.2009.09020284
Bauer M, Crossley NA, Gerber S, Bschor T: The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In Lithium in Neuropsychiatry. The Comprehensive Guide. Edited by: Bauer M, Grof P, Müller-Oerlinghausen B. Informa Healthcare, London; 2006:109–128. 10.3109/9780203007051
Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M: Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 2014,28(4):331–342. 10.1007/s40263-014-0152-8
Blackwell B, Shepherd M: Prophylactic lithium: another therapeutic myth? An examination of the evidence to date. Lancet 1968,1(7549):968–971. 10.1016/S0140-6736(68)90917-3
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JC-Y, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RMA, Wozniak PJ: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000,57(5):481–489. 10.1001/archpsyc.57.5.481
Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003,60(4):392–400. 10.1001/archpsyc.60.4.392
Bschor T, Uhr M, Baethge C, Lewitzka U, Ising M, Erbe S, Winkelmann P, Ritter D: Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. J Clin Psychopharmacol 2013,33(1):38–44. 10.1097/JCP.0b013e31827b9495
Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G: Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001, 3: CD003013.
Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003,64(9):1013–1024. 10.4088/JCP.v64n0906
Calabrese JR, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, Gajwani P, Pies R: Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004,56(12):957–963. 10.1016/j.biopsych.2004.09.022
Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J: Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006, 4: CD003492.
Cipriani A, Hawton K, Stockton S, Geddes JR: Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013, 346: f3646. 10.1136/bmj.f3646
Coxhead N, Silverstone T, Cookson J: Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992,85(2):114–118. 10.1111/j.1600-0447.1992.tb01453.x
Crossley NA, Müller-Oerlinghausen B, Glenn T, Bauer M: The position of lithium in international and national guidelines for the treatment of mood disorders. In Lithium in Neuropsychiatry. The Comprehensive Guide. Edited by: Bauer M, Grof P, Müller-Oerlinghausen B. Informa healthcare, London; 2006:33–42. 10.3109/9780203007051-7
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986,7(3):177–188. 10.1016/0197-2456(86)90046-2
Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR: Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry 2006,67(11):1721–1728. 10.4088/JCP.v67n1108
Geddes JR, Miklowitz DJ: Treatment of bipolar disorder. Lancet 2013,381(9878):1672–1682. 10.1016/S0140-6736(13)60857-0
Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM: Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004,161(2):217–222. 10.1176/appi.ajp.161.2.217
Geddes JR, Calabrese JR, Goodwin GM: Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009,194(1):4–9. 10.1192/bjp.bp.107.048504
Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E: Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010,375(9712):385–395. 10.1016/S0140-6736(09)61828-6
Goodwin GM: Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994,164(2):149–152. 10.1192/bjp.164.2.149
Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004,65(3):432–441. 10.4088/JCP.v65n0321
Greenland S, Robins JM: Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985,41(1):55–68. 10.2307/2530643
Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997,43(2):151–161. 10.1016/S0165-0327(96)01427-9
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S: WFSBP Task Force on Treatment Guidelines for Bipolar Disorders: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013,14(3):154–219. 10.3109/15622975.2013.770551
Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, Chou JC, Wassef A, Risch CS, Hirschfeld RM, Nemeroff CB, Keck PE Jr, Evans DL, Wozniak PJ: Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003,28(7):1374–1382. 10.1038/sj.npp.1300190
Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA: Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003,64(2):144–151. 10.4088/JCP.v64n0206
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003,327(7414):557–560. 10.1136/bmj.327.7414.557
Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002,59(6):530–537. 10.1001/archpsyc.59.6.530
Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A: Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982,39(9):1065–1069. 10.1001/archpsyc.1982.04290090053011
Katona CL: Refractory depression: a review with particular reference to the use of lithium augmentation. Eur Neuropsychopharmacol 1995,5(Suppl):109–113. 10.1016/0924-977X(95)00031-J
Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK: Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011,199(1):57–63. 10.1192/bjp.bp.110.084822
Kessing LV, Hellmund G, Andersen PK: An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 2012,26(5):644–652. 10.1177/0269881111414091
Licht RW: Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther 2012,18(3):219–226. 10.1111/j.1755-5949.2011.00260.x
Licht RW, Severus E: Letter to the editor: is it valid to break down results from long-term trials in bipolar disorder by polarity of relapses? Int J Bipolar Disord 2014,2(8):ᅟ. Ref Type: Journal (Full). http://www.journalbipolardisorders.com/content/2/1/8
Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H: Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010,12(5):483–493. 10.1111/j.1399-5618.2010.00836.x
Malhi GS, Tanious M, Das P, Berk M: The science and practice of lithium therapy. Aust N Z J Psychiatry 2012,46(3):192–211. 10.1177/0004867412437346
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959,22(4):719–748.
Markar HR, Mander AJ: Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry 1989, 155: 496–500. 10.1192/bjp.155.4.496
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR: Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012,379(9817):721–728. 10.1016/S0140-6736(11)61516-X
Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, Cipriani A, Geddes JR, Kanba S: Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014,1(5):351–359. 10.1016/S2215-0366(14)70314-1
Moher D, Liberati A, Tetzlaff J, Altmann DG: The Prima Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009,6(7):e1000097. 10.1371/journal.pmed.1000097
Moncrieff J: Lithium: evidence reconsidered. Br J Psychiatry 1997, 171: 113–119. 10.1192/bjp.171.2.113
NIMH/NIH Consensus Development Conference statement: Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel Am J Psychiatry 1985,142(4):469–476. 10.1176/ajp.142.4.469
Pfennig A, Bschor T, Baghai T, Braunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M: S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt 2012,83(5):568–586. 10.1007/s00115-011-3415-3
Prien RF, Caffey EM Jr, Klett CJ: Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973,28(3):337–341. 10.1001/archpsyc.1973.01750330035006
Quitkin F, Rifkin A, Klein DF: Prophylaxis of affective disorders. Current status of knowledge. Arch Gen Psychiatry 1976,33(3):337–341. 10.1001/archpsyc.1976.01770030051007
R Development Core Team. R:A Language and Environment for Statistical Computing, Reference Index version 2.x.x. R Foundation for Statistical Computing, Vienna, Austria; 2005.
Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E: Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther 2011,17(3):167–177. 10.1111/j.1755-5949.2009.00089.x
Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340: c332. 10.1136/bmj.c332
Severus WE, Kleindienst N, Seemuller F, Frangou S, Moller HJ, Greil W: What is the optimal serum lithium level in the long-term treatment of bipolar disorder- a review? Bipolar Disord 2008,10(2):231–237. 10.1111/j.1399-5618.2007.00475.x
Severus WE, Lipkovich IA, Licht RW, Young AH, Greil W, Ketter T, Deberdt W, Tohen M: In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry 2010,25(8):443–449. 10.1016/j.eurpsy.2009.10.009
Suppes T, Baldessarini RJ, Faedda GL, Tohen M: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991,48(12):1082–1088. 10.1001/archpsyc.1991.01810360046007
Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M: Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry 1993,1(3):131–144. 10.3109/10673229309017072
The Cochrane Collaboration:Review Manager (RevMan) [Computer program]. Version 5.3. The Nordic Cochrane Center, http://tech.cochrane.org/revman/about-revman-5, editors. ᅟ, Copenhagen; 2014.
Toerien M, Brookes ST, Metcalfe C, de Salis I, Tomlin Z, Peters TJ, Sterne J, Donovan JL: A review of reporting of participant recruitment and retention in RCTs in six major journals. Trials 2009, 10: 52. 10.1186/1745-6215-10-52
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005,162(7):1281–1290. 10.1176/appi.ajp.162.7.1281
Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M: The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009,11(5):453–473. 10.1111/j.1399-5618.2009.00726.x
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B: Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011,72(11):1452–1464. 10.4088/JCP.11m06878
Wolf C, Berky M, Kovacs G: Carbamazepine versus lithium in the prophylaxis of bipolar affective disorders. A randomised, double-blind 1-year study in 168 patients. Eur Neuropsychopharmacol 1997,7(Supplement 2):S176. Ref Type: Journal (Full) 10.1016/S0924-977X(97)88579-3
Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision) Am J Psychiatry 2002,159(4 Suppl):1–50. http://www.ncbi.nlm.nih.gov/pubmed/11958165